Choroidal neovascularization(CNV)is a common severe complication of ocular fundus diseases, with great potentiality to cause blindness. The treatments of CNV include photodynamic therapy(PDT)and anti-vascular endothelial growth factor(VEGF)therapy. However, PDT produces little visual benefits, and may result in ischemia, inflammatory responses, even the secondary expressions of VEGF. Anti-VEGF therapy sustained visual efficiency by repeated injections, causing economic burden and adverse effects related to injection. Recently, PDT combined with anti-VEGF therapy has progressed in laboratory and clinical research. Therefore, the combined modality therapy became one of the treatment options for CNV. In order to reduce the side effects of mono-therapy, further study is required to determine appropriate combinations and dosage.